Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05063994 · ClinicalTrials.gov registry record · Phase 3
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
A Phase 3 study, sponsored by Neurocrine UK Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
NCT05063994 is a Phase 3 study that has completed, run by Neurocrine UK Limited. The registered enrollment target is 55 participants.
The verdict
NCT05063994, a Phase 3 study, has completed, sponsored by Neurocrine UK Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.
Interventions
- OTHER Placebo
- DRUG Chronocort
- DRUG Cortef
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2022-05-24 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05063994
The ClinicalTrials.gov registry entry for NCT05063994 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine UK Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05063994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05063994 about?
NCT05063994 is a clinical study titled "Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia". This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.
What is the current status of trial NCT05063994?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2022-05-24. Estimated completion is 2024-02-02.
What interventions are being tested in trial NCT05063994?
The interventions under investigation include: Placebo (OTHER), Chronocort (DRUG), Cortef (DRUG).
Who is sponsoring clinical trial NCT05063994?
This trial is sponsored by Neurocrine UK Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.